article · Cancer Management and Research

A Pharmacogenomic Basis for Tolerance of 5-Fluorouracil Following Early, Severe Toxicity from Capecitabine in a CDA Ultrarapid Metabolizer Colon Cancer Patient: A Case Report

Tinashe Mazhindu
Zedias Chikwambi
Margaret Borok
Edith Matsikidze
Ntokozo Ndlovu
Kevin Grimes
Collen Masimirembwa

2026Open accessUniversity of Zimbabwe

Abstract

This case shows that the severe adverse effects of capecitabine therapy in a patient with a CDA ultrametabolizer profile can be successfully switched to 5-FU-based therapy at a normal dose and tolerate this alternative fluoropyrimidine.

Research topics

Colorectal Cancer Treatments and Studies
Cancer Treatment and Pharmacology
Genetic factors in colorectal cancer

Sustainable Development Goals

Good Health and Well-being

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.2147/cmar.s571794

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.